Tucidinostat
Hormone Receptor-Positive Breast Cancer
Explore 112 assets in Hormone Receptor-Positive Breast Cancer →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05890287CT.gov A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy | — | Recruiting | — | — | — |
NCT05806047CT.gov Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy | — | Unknown | — | — | — |
NCT05808582CT.gov Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer | — | Unknown | — | — | — |
NCT05633914CT.gov Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer | — | Unknown | — | — | — |
NCT05335473CT.gov Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hormone Receptor-Positive Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tucidinostat (this asset) | Tianjin Medical University Cancer Institute and Hospital | P2 | B · 60 |
| Exemestane | Fujian Cancer Hospital | P4 | BBB |
| Everolimus | Ellipses Pharma | P4 | BBB |
| Anastrozole | University of Illinois at Chicago | P4 | BBB |
| Ribociclib | BeOne Medicines | P4 | BBB |
| Palbociclib | BeOne Medicines | P3 | BBB |
| Abemaciclib | BeOne Medicines | P4 | BBB |
| Capecitabine | Kristina A. Fanucci | P4 | BBB |
| Elacestrant | West German Study Group | P3 | BB |
+42 more in the Hormone Receptor-Positive Breast Cancer cohort
Other indications for Tucidinostat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Extranodal Nasal NK/T Cell Lymphoma | — | P4 | BB · 70 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P4 | BB · 69 |
| Acute Lymphoblastic Leukemia | — | P2/3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tucidinostat in Hormone Receptor-Positive Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tucidinostat-hormone-receptor-positive-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →